ResearchMoz

Avastin (Breast Cancer) Analysis and Forecasts to 2020

GlobalData
Published Date » 2011-12-31
No. Of Pages » 47
 GlobalDatas pharmaceuticals report, Avastin (Breast Cancer)  Analysis and Forecasts to 2020 provides Avastin sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2007-2020). The report also includes information on Breast Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.  Note: This is a on-demand...
Table of Contents

1 Table of contents 2
1.1 List of Tables 3
1.2 List of Figures 3

2 Introduction 5
2.1 Breast Cancer Market 5
2.2 Epidemiology 5
2.3 GlobalData Analysis and Estimates Report Guidance 7

3 Breast Cancer: Market Characterization 8
3.1 Breast Cancer Market 8
3.2 Breast Cancer Market Forecasts and CAGR 8
3.3 Drivers of Breast Cancer Market 9
3.3.1 High Prevalence 9
3.3.2 Breast Cancer: Most Frequent Cancer in Women 9
3.3.3 Increasing Breast Cancer Incidence Rate 10
3.3.4 Decreasing Breast Cancer Mortality Rate 11
3.3.5 High Survival Rates of Breast Cancer 14

4 Staging of Breast Cancer: Introduction 15
4.1 Distribution of Patients by Stages 15
4.1.1 Stages 15

5 Predictive Biomarker in the Treatment of Breast Cancer 18

6 Treatment Options of Breast Cancer 20

6.1 Stage 0 Breast Cancer: Treatment Options 20
6.2 Early Stage Breast Cancer (Excluding Stage 0) 21
6.3 Metastatic Breast Cancer (MBC) 23
6.3.1 Endocrine treatment: Adjuvant, First Line and Second Line 23
6.3.2 Cytotoxic Chemotherapy 25
6.3.3 Management of Patients with HER-2 Positive Patients 27

7 Avastin (bevacizumab) 29
7.1 Introduction 29
7.2 Mechanism of Action 29
7.3 Clinical Studies 29
7.4 Approval History of Avastin 30
7.5 Factors Affecting Sales of Avastin 31
7.5.1 Breast Cancer Market 31
7.5.2 Efficacy 31
7.5.3 Approval in Japan 31
7.5.4 Withdrawal of Approval in the US and Rejection in the UK 31
7.5.5 EMAs Verdict 31
7.6 Drug Evaluation 31
7.6.1 Drug Risk Benefit Score 31
7.6.2 Intensity of Competition 32
7.7 Sales Forecasts 32
7.7.1 Target Patient Pool of Avastin 33
7.7.2 Dosing 33
7.7.3 Market Penetration 34
7.7.4 Annual Cost of Therapy 34
7.7.5 Sales Projections of Avastin 34

8 Breast Cancer Market: Appendix 43
8.1 Market Definitions 43
8.2 Abberiviations 43
8.3 Research Methodology 43
8.3.1 Coverage 44
8.3.2 Secondary Research 44
8.3.3 Forecasting 44
8.3.4 Number of Patients Approved to take the Drug 44
8.3.5 Net Penetration of Drug 45
8.3.6 Net Annual Dosing 46
8.3.7 Annual Cost of Therapy 46
8.3.8 Primary Research 46
8.3.9 Expert Panels 46
8.4 Contact Us 47
8.5 Disclaimer 47
8.6 Sources 47

List of Tables


Table 1: Breast Cancer, Incidences and Mortality, By Country, 2008-2030 5
Table 2: Breast Cancer, Global, Market Size Forecasts ($bn), 20102020 8
Table 3: Five-Year Relative Survival Rates, By Stages 14
Table 4: Phase III Clinical Study (E2100) Results for Avastin in Metastatic Breast Cancer 29
Table 5: Approval History of Avastin 30
Table 6: Drug Risk Benefit Score of Avastin 32
Table 7: Avastin, Breast Cancer, The US, The UK, France, Germany, Italy and Spain, Sales Estimates ($m), 20072010 35
Table 8: Avastin, Breast Cancer, France, Germany, Italy, Spain and Japan, Sales Forecasts ($m), 20072020 35
Table 9: Avastin, Breast Cancer, The US, Sales Estimates ($m) 20082010 36
Table 10: Avastin, Breast Cancer, The UK, Sales Estimates ($m) 20072010 37
Table 11: Avastin, Breast Cancer, France, Sales Forecasts ($m) 2007-2020 38
Table 12: Avastin, Breast Cancer, Germany, Sales Forecasts ($m) 20072020 39
Table 13: Avastin, Breast Cancer, Italy, Sales Forecasts ($m) 20072020 40
Table 14: Avastin, Breast Cancer, Spain, Sales Forecasts ($m) 20072020 41
Table 15: Avastin, Breast Cancer, Japan, Sales Forecasts ($m) 20112020 42

List of Figures


Figure 1: Distribution by Incidence and Mortality, Most Commonly Diagnosed Cancers, Worldwide, 2010 6
Figure 2: Breast Cancer, Global, Market Size Forecasts ($bn), 20102020 8
Figure 3: Top Ten Most Frequent Cancers on Incidence-Mortality Matrix, Worldwide, 2010 9
Figure 4: Incidence per 100,000, Breast Cancer, Selected Countries, 1975-2005 10
Figure 5: Incidence per 100,000, Breast Cancer, Selected Countries, 1975-2005 10
Figure 6: Breast Cancer, Incidence, Worldwide, 2008-2030 11
Figure 7: All Cancers, Incidence, Worldwide, 2008-2030 11
Figure 8: Mortality per 100,000, Breast Cancer, Selected Countries, 1975-2005 12
Figure 9: Mortality per 100,000, Breast Cancer, Selected Countries, 1975-2005 12
Figure 10: Breast Cancer, Mortality, Worldwide, 2008-2030 13
Figure 11: All Cancers, Mortality, Worldwide, 2008-2030 13
Figure 12: Broad Classification of Breast Cancer, By Type 15
Figure 13: Classification of Non-Invasive Breast Cancer, By CIS 15
Figure 14: Classification of Invasive Breast Cancer, By Stages 16
Figure 15: Classification of Invasive Breast Cancer, By Treatment 16
Figure 16: Classification of Metastatic or Advanced Breast Cancer 16
Figure 17: Classification of Early Stage Breast Cancer (Excluding Stage 0) 17
Figure 18: Classification of Locally Advanced Breast Cancer 17
Figure 19: Metastatic Breast Cancer Classification 17
Figure 20: Current Molecular Biomarkers used in the Clinical Management of Breast Cancer 18
Figure 21: Breast Cancer Intrinsic Sub Types used for Deciding Treatment Options for MBC 19
Figure 22: Breast Cancer Types in Decreasing Order of their Aggressiveness 19
Figure 23: Treatment Options, DCIS Breast Cancer 20
Figure 24: Treatment Options, LCIS Breast Cancer 21
Figure 25: Treatment Options, Stages I, II and IIIA 21
Figure 26: Treatment Options, Stages I, II and IIIA (HR Positive and Premenopausal Breast Cancer) 22
Figure 27: Treatment Options, Stages I, II and IIIA (HR Negative, Pre and Postmenopausal Breast Cancer) 22
Figure 28: Treatment Options, Stages I, II and IIIA (HR Positive Postmenopausal Breast Cancer) 23
Figure 29: Adjuvant Therapy for HR Positive, HER2 Negative Metastatic Breast Cancer 24
Figure 30: Hormonal Therapy in Adjuvant Setting in HR Positive, HER2 Negative MBC 24
Figure 31: Adjuvant and First Line Therapy for HR Negative, HER2 Negative Metastatic Breast Cancer 26
Figure 32: Treatment Options, HR Negative and HER2 Positive Metastatic Breast Cancer 27
Figure 33: Drug Model Diagram of Avastin 33
Figure 34: Avastin, Breast Cancer, Global, Sales Forecasts ($m), 20072020 35
Figure 35: Avastin, Breast Cancer, The US, Sales Estimates ($m) 20082010 36
Figure 36: Avastin, Breast Cancer, The UK, Sales Estimates ($m) 20072010 37
Figure 37: Avastin, Breast Cancer, France, Sales Forecasts ($m) 2007-2020 38
Figure 38: Avastin, Breast Cancer, Germany, Sales Forecasts ($m) 20072020 39
Figure 39: Avastin, Breast Cancer, Italy, Sales Forecasts ($m) 20072020 40
Figure 40: Avastin, Breast Cancer, Spain, Sales Forecasts ($m) 20072020 41
Figure 41: Avastin, Breast Cancer, Japan, Sales Forecasts ($m) 20112020 42
Figure 42: Drug Model Diagram 45
Figure 43: Patients Approved for the Drug 46

Upcoming Reports:

Outsourcing Automotive Manufacturing Market - Global Industry Analysis, Market Size, Share, Growth, Trends, and Forecast, 2012 - 2018
By - Transparency Market Research
Outsourcing has become a popular global issue and the automotive manufacturing industry is now in line with this growing trend. With an increase in globalization, outsourcing is seen as an opportunity to tap the global market. India and China are regarded as a huge potential market due to their growth in infrastructure and easy availability of educated and trained labor.  In India and China, labor can be hired at very reasonable rates and these countries have become the global hub for automotive industry manufacturers.  Automotive manufacturers have opened...
Greece: bakers yeast market
By - Williams and Marshal Strategy
nd the factors, influencing its development. Last but not least, the report presents a general overview of the economy of Greece in 2008-2012 and a forecast for its development in the medium term. The report on the bakers yeast market in Greece includes: Analysis and dynamics of the economy of Greece; Forecast for the development of the economy of Greece; Analysis and forecast of market volume and dynamics; Volume, dynamics and analysis of domestic production; Characteristics of market structure (by origin, by types of products, etc.); Analysis of price level and dynamics; Volume,...
Poland: fertilizer distributors market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the fertilizer distributors market in Poland and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the fertilizer distributors market in Poland, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Ford Recalls 65,000 Fusion Models Due to Issues in Ignition Key
Nov 20, 2014  
If anything defines the world of automobiles currently, it would be recalls. It seems that a flood of automobiles has surrounded the global automobiles industry, which once represented a flourishing and highly profitable industry.  The current automobile giants ordering yet another recall is Ford Motors Co. Ford declared on Tuesday that it is recalling nearly 65,000 sedans from...
3D Printed Heart Model for Better Cardiological Treatment
Nov 20, 2014  
According to research carried out by the American Heart Association’s Scientific Sessions 2014, surgeons will be able to treat complex heart disorders in patients, with the help of a three dimensional experimental printed model of the heart. For surgical planning, most cardiac surgeons make use of two dimensional images of the heart taken by MRI, ultrasound, and X-ray. But the problem is...
Los Angeles Auto Show Kicks Off
Nov 20, 2014  
The Los Angeles Auto Show kicked off on Wednesday with a rather upbeat mood. Motoring machines, industry metrics, and hybrid models – the show has lived up to its reputation once more. The Los Angeles Auto Show has begun touring North America from the Los Angeles Convention Center, and the commencement has already had an impact on the market. Gasoline prices dropped under US$3...
Scottish Government to Inject 200 Million Pounds in the Housing Sector
Nov 19, 2014  
The construction and the housing industries of Scotland will get a major financial boost from the Scottish government in terms of additional funding worth 200 million pounds. The main rationale of such a financial boost is to stimulate the housing sector and also safeguarding employment in the construction industry. The housing minister of Scotland has requested the housing leaders to work...
Quarterly Dividend of $0.10 Declared by Tyson Foods, Inc.
Nov 19, 2014  
A quarterly dividend on November 18th was declared by Tyson Foods, reported Analyst Ratings Network.com. The shareholders of the February 27th record will be awarded a dividend of 0.10 per share on March 13th.  This represents a yield of 0.94% and a $0.40 dividend on an annualized basis. However, the ex-dividend date of this particular dividend is February 25th.  Such...